PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy

Mayo Clinic logo

Mayo Clinic

Status and phase

Completed
Phase 2
Phase 1

Conditions

Cancer

Treatments

Diagnostic Test: PET/CT
Drug: radioactive drug (tracer)

Study type

Interventional

Funder types

Other

Identifiers

NCT04538950
19-009189

Details and patient eligibility

About

Researchers are trying to determine the side effects on the heart from immune checkpoint inhibitor (ICI) treatment in patients with cancer.

Enrollment

6 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • First time administration of ICI
  • Willing and able to return in 4-6 weeks for follow-up study
  • Patients with previous heart conditions included (while this may impact MFR the delta MFR is what we are assessing)

Exclusion criteria

  • Age < 18 years
  • Women who are pregnant, or breast-feeding.
  • Unable or unwilling to give consent to undergo PET/CT.

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

6 participants in 1 patient group

Checkpoint Inhibitor (ICI)
Other group
Description:
Subjects diagnosed with cancer and will be receiving immune checkpoint inhibitors as treatment standard of care will have a PET/CT scan before and after therapy. PET/CT scan is done for study purposes only.
Treatment:
Drug: radioactive drug (tracer)
Diagnostic Test: PET/CT

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems